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Abstract Cyclic aristeromycin diphosphate ribose, a carbocy- 
clic analogue of cyclic adenosine diphosphate ribose, was syn- 
tbesised using a chemo-enzymatic route involving activation of 
aristeromycin 5'-phosphate by diphenyl phosphochloridate. The 
calcium-releasing properties of this novel analogue were investi- 
gated in sea urchin egg homogenates. While cyclic aristeromycin 
diphosphate ribose has a calcium release profile similar to that 
of cyclic adenosine diphosphate ribose (ECso values are 80 nM 
and 30 riM, respectively), it is degraded significantly more slowly 
(tu2 values are 170 rain and 15 rain, respectively) and may, there- 
fore, be a useful tool to investigate the activities of cyclic ade- 
nosine diphosphate ribose. 
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1. Introduction 
Cyclic adenosine diphosphate ribose (cADPR (1); Fig. 1) is 
a novel Ca2+-releasing second messenger candidate. As a natu- 
rally occurring metabolite of nicotinamide adenine dinucleotide 
(NAD +, (2); Fig. 2) [1], it is known to be more effective than, 
and to work independently of, inositol 1,4,5-trisphosphate in 
mobilising internal stores of calcium in sea urchin eggs [2]. Since 
its discovery in 1987 [3], cADPR has been shown to be present 
and active in a wide variety of mammalian and invertebrate 
tissue [4-6] and its cyclic structure has been confirmed by X-ray 
crystallography [7]. The metabolic pathway of cADPR is 
known (Fig. 2) and evidence xists to suggest hat in human 
lymphocytes CD38, a surface antigen, acts as a bifunctional 
enzyme both for synthesising and degrading cADPR [8,9]. 
Mounting evidence has led to the proposal that, by modulat- 
ing the ryanodine receptor, cADPR is an endogenous activator 
of Ca2+-induced Ca 2+ release (CICR) [10]. In addition, there is 
intense interest in the role of cADPR as a potential second 
messenger and its action has been proposed to have a role in 
insulin release [6]. To corroborate this, cGMP has been shown 
to mobilise intracellular Ca 2+ release in sea urchin eggs by 
stimulating cADPR synthesis [11]. The recent discovery that 
cADPR acts through binding to calmodulin to sensitise the 
CICR mechanism to Ca 2+ ions has, for the first time, enabled 
these two proposed mechanisms of action to be linked. It ap- 
pears that, when a large amount of cADPR is synthesised 
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through a proposed second messenger pathway, the CICR 
mechanism is sensitised to such an extent hat the basal level 
of Ca 2+ ions alone will activate further calcium release [12]. 
Structural analogues of cADPR are currently urgently re- 
quired as pharmacological tools for the investigation of its 
biological properties. Since to date there is no total chemical 
synthesis of cADPR (although fl-NAD ÷ has been cyclised 
chemically using NaBr in dimethyl sulphoxide to yield cADPR 
[13]), we, like others [14], have relied upon a chemo-enzymatic 
approach both to prepare cADPR itself and to generate struc- 
tural diversity (Fig. 3) [15]. The route involves first a chemical 
coupling of nucleotides resulting in NAD ÷, or an appropriate 
analogue, and second an enzymatically mediated cyclisation to 
form the natural or modified cADPR, respectively. A key re- 
quirement of this approach for the synthesis of structural ana- 
logues of cADPR is the loose substrate specificity of the en- 
zyme. Our laboratory has already shown this to be a reasonable 
assumption. 
Using our route, but with a modified coupling procedure we 
have synthesised the first carbocyclic analogue of cADPR, cy- 
clic aristeromycin diphosphate ribose (cArisDPR (3); Fig. 1), 
wherein the adenosine ribosyl moiety has been replaced with 
a carbocyclic 5-membered ring. In a comparative study with 
cADPR, this analogue was evaluated for its pharmacological 
characteristics in sea urchin egg homogenates. We report here 
that, while cArisDPR has a similar calcium release profile to 
cADPR, it is significantly longer acting and is presumably 
poorly hydrolysed. 
2. Materials and methods 
2.1. Materials 
Aristeromycin ((4); Fig. 3) was a generous gift of Glaxo (Greenford, 
UK). ADP-ribosyl cyclase was isolated from Aplysia californka as 
described [16] and was used crude. Nicotinamide mononucleotide 
(NMN) and 2-[4-(2-hydroxyethyl) piperazin-l-yl] ethanesulphonic a id 
o%-o. ? 
HO OH X=O, cADPR (1) 
X=CH2, cArisDPR (3) 
Fig. 1. The structure of cADPR (1) and cArisDPR (3). 
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Fig. 2. The metabolic pathway of cADPR showing the structures of 
cADPR, NAD ÷ and ADPR. 
(HEPES) were purchased from Sigma (London, UK). Fluo-3 dye was 
purchased from Calbiochem. High-performance liquid chromatogra- 
phy (HPLC) was performed on a Shimadzu LC-6A with the UV detec- 
tor operating at 259 nm and using a 10-pm Partisil SAX anion-ex- 
change column isocratically eluted with 0.05 M KH2PO415% MeOH 
buffer. Ion-exchange chromatography was performed using an LKB 
Gradifrac System with the column packed with Q-Sepharose Fast Flow 
resin (Pharmacia) in the bicarbonate form. Gradient elution was per- 
formed using an ion-exchange buffer system of triethylammonium bi- 
carbonate. All other chemicals were purchased from Aldrich Chemical 
and solvents were distilled and dried before use. 31p NMR spectroscopy 
was performed on a Jeol EX400 spectrometer operating at 161.9 MHz. 
Chemical shifts are expressed as negative when downfield of external 
85% H3PO 4. UV spectra were recorded on a Perkin-Elmer Lambda-3 
UV/Vis spectrometer using quartz cells (1 cm path length). 
2.2. Chemistry 
Aristeromycin (4) was phosphorylated selectively at the 5' position 
using POCI 3 in a similar fashion to the method eveloped by Yoshikawa 
et al. [17] (2 equivalents POCI 3 in PO(OEt)3, 6 h at 0°C, then quench 
with an excess of iced water) and the resulting phosphate purified by 
ion-exchange chromatography. This nucleotide was activated for cou- 
pling using diphenylphosphochloridate (DPPC, 1.5 equivalents, a 2:1 
ratio of dioxane and DMF, 2 h at 20°C) and was coupled without 
isolation of the intermediate (5) by addition ofT, Y-diacetyl NMN (0.5 
equivalents, a 1:1 ratio of pyridine and DMF, 18 h at 20°C). NMN itself 
was acetylated with acetic anhydride (pyridine, 18 h at 4°C) and used 
immediately [18]. The resulting pyrophosphate coupled product was 
deacetylated with methanolic ammonia (1 : i methanol/conc NH3, 6 h 
at 0°C) to give (6) which was purified by ion-exchange chromatogra- 
phy. Cyclisation of (6) to cArisDPR (3) was performed enzymatically 
using ADP-ribosyl cyclase from Aplysia californica and the conversion 
was monitored by HPLC (1.5 mM cArisDPR, 25 mM HEPES, 10/.d 
enzyme, 0.5 h at 20°C). The product was purified by ion-exchange 
chromatography (40% yield) and quantified using UV analysis assum- 
ing the extinction coefficient o be the same as that of cADPR. This 
assumption was made based on the knowledge that the extinction 
coefficient of aristeromycin s the same as for adenosine [19]. The UV 
data for the final product was 2ma x = 260 nm with e = 14.3 x 103M -t. 
Full synthetic details will be reported elsewhere. 
2.3. Calcium release measurements 
Lytechinuspictus homogenate (2.5%), as previously described [3], was 
incubated at 17°C in an intracellular-like medium (Im) containing an 
ATP-regenerating system, mitochondrial inhibitors and Fluo-3 (3/.tM). 
Extramicrosomal Ca 2+ was measured by monitoring Fluo-3 fluores- 
cence (excitation 490 nm and emission 535 nm) in a Perkin-Elmer 
LS-50B fluorimeter. Additions to the cuvette were between 5and 10/tl 
in Im with 10/.tM EGTA. 
2.4. Monitoring the metabolism of cADPR and cArisDPR 
Degradation of cADPR and cArisDPR (500 nM) in egg homogenate 
was determined using the Ca 2+ release bioassay as above. At appropri- 
ate time intervals, 50-/.tl samples were taken and assayed for remaining 
cXDPR (where X = A or Aris). Ca z+ release, following addition of the 
test sample to 500/11 of assay homogenate, was related to cXDPR 
concentration from a standard curve. Caffeine (1 mM) was added prior 
to the sample to increase sensitivity of the bioassay by approximately 
10-fold, allowing measurement of cXDPR in the sample in the range 
20-500 nM. 
3. Results and discussion 
Aristeromycin 5'-monophosphate was prepared by selective 
phosphorylation of the 5' hydroxyl group using established 
methodology. The crude product was precipitated from the 
reaction residue using acetone and then purified by ion-ex- 
change chromatography. I f  necessary, further precipitations of 
the free acid form of the nucleotide using acetone/water were 
carried out until a ratio of less than 5: 1 nucleotide: inorganic 
phosphate was seen by 31p NMR spectroscopy. The product 
showed a broad single peak in the 31p NMR spectrum, with 
8p = 0.06 ppm which sharpened on broad band proton irradia- 
tion. In our experience, these precipitation steps were essential 
in order to minimise complications in the subsequent phos- 
phate-coupling step arising from contaminating inorganic 
phosphate. 
NAD ÷ analogues have previously been synthesised by cou- 
pling adenosine monophosphate analogues to NMN using 
dicyclohexylcarbodiimide [20]and !-ethyl-3(3-dimethyl-amino- 
propyl)-carbodiimide-HC1 [ 4]. However, we favoured the 
more chemically flexible method of Michelson [21]. The nucle- 
otide was activated using DPPC in dry dioxane and dry DMF 
to produce a mixed anhydride intermediate. The residue after 
evaporation was dissolved in a mixture of dry DMF and dry 
pyridine and treated with the phosphate monoanion of NMN 
(2', Y-diacetyl form which had much greater solubility than the 
unprotected form), which displaced the acidic diphenyl phos- 
phate moiety to give a pyrophosphate. Treatment of this pyro- 
phosphate with methanolic ammonia nd subsequent purifica- 
tion of the resulting product by ion-exchange chromatography 
led to nicotinamide aristeromycin dinucleotide (NArisD + (6)). 
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Fig. 3. The chemo-enzymatic route used to synthesise analogues of 
cADPR showing the structures of NArisD + and cArisDPR. 
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The 31p NMR spectrum of this compound exhibited an AB 
quartet with gp = -11.08 ppm and -11.86 ppm and Jpp = 20.8 
Hz. 
Enzymatic cyclisation of NArisD ÷ (6) was performed accord- 
ing to the protocol previously detailed from this laboratory [15] 
and the formation of the cyclised product, cArisDPR (3), was 
monitored by HPLC (Fig. 4). The retention times for NArisD+, 
cArisDPR and nicotinamide were 2.49 min, 3.84 min and 1.80 
min, respectively, and the reaction was assumed to be complete 
when the peak assigned to nicotinamide in the sample was no 
longer increasing. The cyclisation mixture was quenched by 
excessive dilution after 30 min, a similar reaction time to that 
required for cADPR itself, and cArisDPR was easily purified 
from a small amount of unreacted starting material and nicoti- 
namide by ion-exchange chromatography. 
cArisDPR, together with the parent compound cADPR, was 
assayed for concentration-dependent Ca2+-mobilising activity 
in sea urchin egg microsomes (Fig. 5a). A maximally effective 
concentration f 1/IM cADPR elicited 2.7 nmol Ca 2÷ release 
when measured in absolute terms. In comparison, the same 
concentration f cArisDPR caused only a slight reduction in 
this value at 2.5 nmol Ca 2* release. The ECso values were 30 nM 
for cADPR and 80 nM for cArisDPR. 
A time course for the degradation of cArisDPR was meas- 
ured straightforwardly b incubating a sample with homoge- 
nate and then testing aliquots for calcium-releasing ability (Fig. 
5b). cADPR was seen to degrade rapidly in this system with its 
CaZ÷-releasing ability falling to near-negligible values of over 
25 min. This was presumably a result of enzymatic cleavage of 
the N<ribosyl bond by cADPR hydrolase. There was also a 
signifcant decrease in releasing potency of over 70% in the first 
10 rain. In contrast, the time course for the degradation of 
cArisDPR was markedly slower. In the first 10 min, there was 
only a 10% reduction in response and Ca 2+ release was still 
observable after 5 h of incubation. 
Carbocyclic analogues of nucleosides and nucleotides have 
proven to be good mimics of their parent compounds although 
;> 
t=0min. 
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t=15min. 
NarisD + 
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h I i I , 
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Fig. 4. Monitoring the cyclisation of NArisD ÷ by HPLC. The enzy- 
matic yclisation was carried out as described insection 2. (a) t = 0 rain, 
NArisD ÷ 100% at 2.49 min. (b) t = 15 rain, cArisDPR is seen at 3.84 
min and the by-product nicotinamide is at 1.80 min. (c) t = 30 min, the 
% of cArisDPR had increased only nominally so the reaction was 
quenched immediately. 
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Fig. 5. Stimulation of Ca z+ wrelease from sea urchin egg homogenates 
by activation with cArisDPR. (a) Concentration dependence ofcADPR 
(n) and cArisDPR (e). cADPR and cArisDPR were assayed for cal- 
cium-mobilising activity as described insection 2.3. The ECso values for 
cADPR and cArisDPR are 30 nM and 80 nM, respectively. (b)Degra- 
dation of cADPR (tt) and cArisDPR (e). Degradation ofsample in egg 
homogenate was measured as described in section 2.4, after addition 
of an initial dose sufficient to give a concentration f 500 nM sample. 
X in cXDPR is either A or Aris. 
often with additional (e.g. antiviral) properties [22]. The re- 
placement of the adenosine ribose moiety of cADPR with a 
carbocyclic ring as in cArisDPR leads to surprising hydrolytic 
stability towards the degrading enzyme ven though it is the 
remote N<ribosyl linkage which is cleaved in the catabolism of 
cADPR. We propose that this could be due to the compound 
binding to the enzyme active site in a similar, but subtly differ- 
ent, conformation to that of cADPR making the hydrolytic 
attack of a water molecule more difficult, although clearly not 
impossible. While cADPR-induced Ca 2+ mobilisation has been 
observed in many tissues and cell lines [23] (and recently also 
in T cells [24]), the possibility that its presence in many others 
remains undetected due to rapid metabolism of endogenously 
added cADPR cannot be excluded. The advent of poorly hy- 
drolysable analogues, uch as cArisDPR, and ultimately com- 
pletely non-hydrolysable compounds will allow the potentially 
wider role of cADPR in signalling to be more easily explored. 
The synthesis of cArisDPR is an important step in this direction 
and this compound will not only be a useful biological tool, but 
230 V.C. Bailey et aL / FEBS Letters 379 (1996) 227-230 
also a key prototype for the design of a fully metabolically 
stable cADPR mimic or antagonist. 
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